Cyltezo® (adalimumab-adbm) and unbranded adalimumab-adbm – Clarification about formulary status

Dynamic Alerts

Site Logo

Health care professionals website

DPL Global Search

DPL Main Nav

DPL Global Search

Breadcrumbs

Text

Cyltezo^® (adalimumab-adbm) and unbranded adalimumab-adbm – Clarification about formulary status

October 2, 2023 - Boehringer Ingelheim announced the launch of adalimumab-adbm, its low list biosimilar to Humira, also interchangeable.

Text

Return to publications

Top